NAVB
Navidea Biopharmaceuticals Inc.
NAVB
NAVB
Delisted
NAVB was delisted on the 5th of October, 2023.
52 hedge funds and large institutions have $7.5M invested in Navidea Biopharmaceuticals Inc. in 2017 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 14 increasing their positions, 10 reducing their positions, and 2 closing their positions.
New
Increased
Maintained
Reduced
Closed
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more funds holding
Funds holding: →
more first-time investments, than exits
New positions opened: | Existing positions closed:
less capital invested
Capital invested by funds: $ → $
30% less call options, than puts
Call options by funds: $30K | Put options by funds: $43K
Holders
52
Holding in Top 10
–
Calls
$30K
Puts
$43K
Top Buyers
| 1 | +$130K | |
| 2 | +$124K | |
| 3 | +$49.1K | |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$41K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
+$25K |
Top Sellers
| 1 | -$335K | |
| 2 | -$105K | |
| 3 | -$71.6K | |
| 4 |
Goldman Sachs
New York
|
-$24.3K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$18.9K |